Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Stock Report

| More

Lupin Receives Tentative FDA Approvals for Generic Nuvigil Tablets and Generic Oracea Capsules

Posted On: 2013-08-13 03:17:43

MSD, one of the world's leading players in 23-valent Pneumococcal Polysaccharide Vaccines category and Lupin Limited have formed an India-specific strategic partnership. Within the scope of partnership, Lupin will have a non-exclusive license to market, promote and distribute 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in India.

Pneumococcal disease is an infection caused by bacteria named Streptococcus pneumoniae and it results in variety of invasive and non-invasive pneumococcal diseases with pneumonia being the most common presentation in adults. Pneumococcal disease kills more patients worldwide than any other vaccine preventable diseases. Worldwide 1.6 million people die of pneumococcal disease every year which translates to 3 people dying every minute. Adults with co morbid conditions like chronic lung disease (COPD etc.), diabetes, chronic heart diseases, chronic liver diseases, immune compromised diseases as well as adults more than 65 years of age are at increased risk for pneumococcal diseases than healthy adults.

A recent study from India showed that the case fatality rate due to invasive pneumococcal disease observed in elderly is 26.4% which is much higher than that in children and highlights the need for preventive interventions in adults1

Identifying this significant risk, this partnership is built on a patient centric model, which will help improve vaccination rate for pneumococcal disease, in particular to high risk population group to help reduce incidence and mortality in adults.

Pneumococcal polysaccharide vaccine (PPV)

- Pneumococcal polysaccharide vaccine (PPV) addresses the need of prevention of pneumococcal disease in India with its proven efficacy and broader coverage.

- PPV23 provides broader coverage and has proven efficacy for prevention of pneumococcal diseases which help addresses the need of prevention of pneumococcal disease in India

- Based on the clinical experience since last 3 decades, PPV23 has good safety profile

- Recent India focused study showed that more than 80% of invasive serotype groups of Streptococcus pneumoniae causing disease in the elderly in India are included in the formulation of PPV 23 which makes this vaccine relevant from India perspective

- PPV23 is recommended worldwide for prevention of pneumococcal diseases in adults by leading medical societies like Advisory committee on Immunization Practices, American Diabetes Association, American Thoracic society, Geriatric society of India etc.

Shares of Lupin Ltd was last trading in BSE at Rs.839.60, up by Rs.20.40 or 2.49%. The stock hit an intraday high of Rs.847.55 and low of Rs.817.60.

The total traded quantity was 0.73 lakhs compared to 2 week average of 1.45 lakhs.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Bliss GVS Pharma Ltd divests Managed Healthcare Services Business to Mayfair Healthcare Holdings Ltd
Bharti Airtel Ltd to transfer 25% share in Bharti Telemedia Ltd
Sicagen India Ltd calls for Board Meeting on Feb 7, 2018
California Software Company Ltd updates on acquisition of Infinia Solutions
Radio City launches one of its kind listener choice award in Maharashtra
Dalmia Bharat Ltd to announce Q3 results on Feb 7, 2018
Suditi Industries Ltd calls for Board Meeting on Jan 25, 2018
Shoppers Stop opened at Big India Mall, Thane and Palladium Mall, Chennai
OCL India Ltd to consider Q3 results on Feb 7, 2018
Rossell India Ltd to consider 3rd quarter results on Feb 9, 2018
Karur Vysya Bank Ltd to announce Q3 results on Jan 31, 2018
Parsoli Corporation Ltd calls for Board Meeting on Jan 25, 2018
SML Isuzu Ltd to announce third quarter results on Feb 9, 2018
Crestchem Ltd calls for Board Meeting on Jan 30, 2018
Prime Urban Development India Ltd calls for Board Meeting on Feb 2, 2018
Bharti Airtel Ltd approves acquisition of 5% in Bharti Teleports Ltd
ICICI Bank announces completion of 8 years tenure by two directors
Prima Plastics Ltd to announce third quarter results on Jan 31, 2018
Himadri Speciality Chemical Ltd calls for Board Meeting On 29 January, 2018
International Combustion India Ltd calls for Board Meeting on Feb 6, 2018
Stellar Capital Services Ltd announces resignation of Independent Directors
Essar Shipping Ltd appoints CFO
GHCL wins Golden Peacock Award for CSR for the year 2017
Esaar India Ltd updates on compliance officer
Sanghvi Movers Ltd to consider 3rd quarter results on Feb 9, 2018
D-Link India Ltd to approve Q3 results on Feb 9, 2018
Bliss GVS Pharma Ltd Q3 net profit up at Rs. 21.67 crores
Sadhana Nitrochem Ltd Q3 net profit zooms to Rs. 8.08 crores
Chennai Petroleum Corporation Ltd Q3 net profit surges to Rs. 386.22 crores
Reliance Industries Ltd Q3 PAT jumps to Rs. 9445 crores
G N A Axles Ltd posts net profit of Rs. 12.68 crores in Q3
JM Financial Ltd Q3 net profit jumps to Rs. 168.09 crores
Wipro Ltd Q3 net profit drops to Rs. 1930.1 crores
Gulshan Polyols Ltd to approve quarterly results on Jan 29, 2018
Voltas Ltd to consider Q3 results on Feb 7, 2018
Mahindra Holidays & Resorts India Ltd announces resignation of Mr. S Krishnan
Unichem Laboratories Ltd to consider quarterly results on Feb 5, 2018
Wipro Ltd Board declares Interim Dividend of Rs. 1 for 2017-18
Alkyl Amines Chemicals Ltd calls for Board Meeting on Feb 5, 2018
HSIL Ltd to consider Q3 results on Jan 29, 2018
AstraZeneca Pharma India Ltd calls for Board Meeting on Feb 5, 2018
Gujarat Poly Electronics Ltd calls for Board Meeting on Jan 30, 2018
Redington India Ltd to approve 3rd quarter results on Feb 1, 2018
Kerala Ayurveda Ltd calls for Board Meeting on Jan 30, 2018
Endurance Technologies Limited calls for Board Meeting on Feb 14, 2018
Gartner Positions Infosys as a Leader in Magic Quadrant for Application Testing Services
Maithan Alloys Ltd to consider Q3 results on Jan 27, 2018
Maharashtra Seamless Ltd calls for Board Meeting on Feb 2, 2018
TCI Finance Ltd calls for Board Meeting on Feb 5, 2018
Madhusudan Industries Ltd calls for Board Meeting on Feb 8, 2018


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018